2023 World Conference on Lung Cancer (Posters)-P1.25. Phase 2 Trial of Neoadjuvant Camrelizumab Plus Chemotherapy or Apatinib for Resectable or Potentially Resectable NSCLC

P1.25. Phase 2 Trial of Neoadjuvant Camrelizumab Plus Chemotherapy or Apatinib for Resectable or Potentially Resectable NSCLC - PDF(Slides)

Back to course

Pdf Summary

A phase 2 study in China evaluated the effectiveness and safety of camrelizumab combined with either chemotherapy or apatinib as neoadjuvant therapy in patients with stage II-III non-small cell lung cancer (NSCLC) that was resectable or potentially resectable. The study included 89 patients, with 58 receiving camrelizumab plus chemotherapy and 31 receiving camrelizumab plus apatinib. The surgery rate was higher in the camrelizumab plus chemotherapy group (78.6%) compared to the camrelizumab plus apatinib group (50.0%). The study also analyzed surgical outcomes and found that the camrelizumab plus chemotherapy group generally had higher response rates, including complete response and partial response. The study concluded that neoadjuvant therapy with camrelizumab plus chemotherapy or apatinib is effective for patients with early-stage NSCLC, but further research is needed to determine the optimal treatment strategy.<br /><br />The study in China focused on evaluating the efficacy and safety of neoadjuvant camrelizumab combined with platinum-doublet chemotherapy or apatinib in patients with stage II-III NSCLC. The primary endpoint was the major pathological response rate, which measures the proportion of patients with minimal residual tumor cells after surgery. Both treatment arms showed promising pathological responses, especially in patients with potentially resectable disease. The surgery rates were higher in the camrelizumab plus chemotherapy arm, and the R0 resection rates were high in both arms. The efficacy analysis showed a significant number of patients achieving major pathological response and pathological complete response in both treatment arms. The radiographic objective response rate, according to RECIST version 1.1, was also high in both arms. The safety profiles of both treatment arms were manageable. The study concluded that neoadjuvant camrelizumab with chemotherapy or apatinib showed promising pathological responses and manageable toxicity in patients with stage II-III NSCLC, particularly in potentially resectable disease. The study suggests that further investigation is needed to explore this treatment approach.

Asset Subtitle

Haoran Xia

Meta Tag

Speaker Haoran Xia

Topic Early-Stage NSCLC: Changing Paradigms & Outcomes

Keywords

Phase 2 study

China

effectiveness

safety

camrelizumab

chemotherapy

apatinib

neoadjuvant therapy

non-small cell lung cancer

NSCLC